What Makes James River Group (JRVR) a Strong Momentum Stock: Buy Now?

James River Group Holdings (NASDAQ: JRVR) reported Q2 2026 results. Net income available to common shareholders was $4.4M, up 59% year over year, and adjusted net operating income was $10.0M. Gross written premium fell to $268.9M, with E&S combined ratio 92.8%. Board declared a $0.01/share cash dividend payable Sept. 30, 2026.

James River Group Holdings, Inc. (JRVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 JAMES RIVER ANNOUNCES SECOND QUARTER 2026 RESULTS Chapel Hill, N.C., August 10, 2026 - James River Group Holdings, Inc. ("James River" or the "Company") (NASDAQ: JRVR) today reported the following results for the second quarter of 2026 as compared to the same period

Netflix laid off 1,000 employees, including top executives like Bela Bajaria, due to slow subscriber growth and content quality concerns. The company's release strategy and cancellation of shows have been criticized. New chief content officer Peter Rice is expected to improve content quality.

Moderna (MRNA) and Merck reported a 42% reduction in melanoma recurrence or death in a Phase 3 trial of Moderna's cancer vaccine. Shares fell 17.6% after data leaked early. The trial tested intismeran autogene with Merck's Keytruda. Moderna reported Q2 2026 loss of $782m on $145m revenue.

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.